Ghana's Medical Equipment Market: Growth, Opportunities, and Regulatory Landscape

Nov 06, 2025 0

Ghana's medical device market is experiencing significant growth and presents numerous opportunities for international companies. According to a report by Statista, revenue in the medical devices market in Ghana is projected to reach $138 million in 2023. Other analysts project that the medical device market in Ghana is poised for significant growth, perhaps even doubling if several favorable conditions are met.

This growth is influenced by various factors, including government policies, healthcare infrastructure development, technological advancements, and healthcare demand. Improvement and expansion of health care is one of the central pillars of the government of Ghana’s human development agenda and is an underlying factor in the government’s overall strategy for accelerated growth in the country.

Let's delve into the current state of the market, key drivers, challenges, and strategies for success.

Key Market Drivers

Several factors are driving the growth of Ghana's medical equipment market:

Government and Private Investments: Increasing investments in healthcare and the launch of new facilities requiring equipment are the largest factors.
Infrastructure Development: In September 2023, Ghanaian President Akuffo Addo noted that 86 public district hospitals, two regional psychiatric hospitals, and the western regional hospital were at various stages of completion.
Expansion of Private Clinics and Hospitals: Further, the expansion of private clinics and large private hospitals in Ghana continues unabated, with three groundbreakings and/or openings in the third quarter of 2023.
Changes in Hospital Supply Chain: Local health professionals also suggest that the growth in the procurement of medical by hospitals and clinics also relates to changes in hospital supply chain and other procedures following the COVID-19 pandemic.

These developments indicate a strong demand for medical equipment and technologies.

Read also: Top CROs in Kenya

Market Segments and Forecasts

The growth of Ghana’s medical market should create opportunities for U.S firms in the areas of hospital design and construction, consulting, and medical technologies ranging from cardiovascular and telemedicine to diagnostic equipment and more. This is a best prospect industry sector for this country. products and investment.

Cardiology Devices: The largest specific subcategory of growth is cardiology devices with a projected market volume of $21 million in 2023.
Consumables: The consumables market, which includes suturing materials, needles, and catheters, is expected to grow by 13.1% to $42.9 million by 2027.
Diagnostic Imaging: The Diagnostic Imaging market is expected to grow to $25.3 million by 2027.
Dental Equipment: The market for Dental Equipment is expected to grow to $2.2 million by 2027.

Forecasts are that Ghana’s medical device market will reach $111 million by 2026.

The major players in the medical device sector in Ghana include Becton Dickinson (BD), GE Healthcare, Mindray, Canon, Johnson & Johnson, Philips, Medtronic, etc.

Figure: Map of Ghana showing the study districts.

Healthcare Infrastructure and Coverage

In terms of health infrastructure, the country has over 91 public hospitals and over 200 private hospitals. There are about 4,300 doctors and 68,000 nurses in the country. The country’s projected market size for health insurance is about $16.5 million and the market size for laboratories, imaging, radiology and pathology services is about $15 million. The pharmaceutical market size is about $438 million and the medical device market size is about $89 million.

The Government of Ghana continues to expand access to healthcare coverage and the scope of benefits it makes available to its citizens. Ghana’s 2021 census results reported 69% of the population was covered by either the National Health Insurance Scheme (NHIS) or private health insurance schemes. There is a higher rate of health insurance coverage for females (73%) than males (65%). Health insurance coverage ranges from a low of 52% in the Oti Region to a high of 86% in the Upper East Region. The National Health Insurance Scheme provides coverage for a limited scope of health issues, primarily insuring for treatment against the most prevalent diseases, such as malaria.

The healthcare sector in Ghana is organized at three different levels: national, regional, and district. Health interventions are packaged for each level and are delivered to the respective clinics and hospitals. Healthcare is variable throughout Ghana. Urban centers are well served, and are where most hospitals, clinics, and pharmacies in the country can be found. Rural areas often have no modern healthcare services. Patients in these areas either rely on traditional African medicine or travel great distances for healthcare. Most healthcare is provided by the government and is largely administered by the Ministry of Health and the Ghana Health Services.

Figure: Regions of Ghana.

The healthcare system has five levels of providers: 1) health posts, the first level of primary care in rural areas; 2) health centers and clinics; 3) district hospitals; 4) regional hospitals; and 5) tertiary hospitals. Ghana spends on average about 6% of its GDP on healthcare infrastructure. The COVID 19 pandemic exposed large gaps in the health sector, including the need to construct more district-level hospitals.

Technological Advancements

Technology has been the driving force behind Ghana’s healthcare development and delivery. A US-EXIM facility retooled the country’s premier hospital, Korle Bu Teaching Hospital, in 2010. Subsequently, the Greater Accra Regional Hospital, popularly known as Ridge Hospital, was also built using US-EXIM financing. Zipline, an American drone delivery company, has deployed drone services to deliver vital medical supplies and consumables to remote parts of the country. The introduction of the National Electronic Pharmacy Platform (e-pharmacy), among other innovations, has advanced the delivery of healthcare in the country.

Read also: Improving Ethiopian Healthcare

Ghana’s primary healthcare system is the foundational level and serves as the entry point into the overall healthcare system. It includes health posts, clinics, and health centers, which primarily provide essential healthcare services such as immunization, malaria treatment, antenatal care, and infant and young child feeding. The secondary level of healthcare is comprised of services provided by specialists. Providers in the primary healthcare segment typically refer patients to this level for cases that require more specialized care, such as cardiology, endocrinology, neurology, ear, nose, and throat (ENT) services, and general surgery. Tertiary healthcare involves higher levels of specialized care, often requiring inpatient services, specialized equipment, and expertise. This level includes advanced procedures such as kidney dialysis, neurosurgery, cardiology and cardiac surgery interventions, assisted reproductive technologies such as IVF, and cancer care.

Regulatory Environment

Navigating Ghana’s regulatory landscape is crucial for market entry. Here's how non-US companies can leverage the US Food and Drug Administration (USFDA) process to streamline approval with Ghana's Food and Drugs Authority (FDA Ghana):

Align with USFDA Priorities: The FDA Ghana prioritizes regulations similar to those of the USFDA, particularly for Software as a Medical Device (SaMD).
Leverage Existing USFDA Work: Identify the equivalent classification in Ghana and utilize the corresponding USFDA requirements.
Proactive Post-Market Planning: Analyze USFDA data to identify potential post-market risks and address them upfront.

The Food and Drugs Authority (FDA) in Ghana is dedicated to ensuring the integrity of food and products, meeting the growing demand for quality consumption. Established in 1992, the FDA is recognized by the World Health Organization and other international regulatory bodies. It must be renewed before 3 months of expiry date.

The labelling information shall include the following:

The name of the device, both „proprietary‟ and „common‟
The name and address of the manufacturer; the manufacturing site address
The identifier of the device, including the identifier of a device that is part of a system, test kit, medical device group, medical device family or medical device group family in the case of a Class III or IV device, the control number, otherwise the batch or lot number
An indication of what the package contains, expressed in terms appropriate to the device, such as size, net weight, length, volume, or number of units
The word “Sterile” if the manufacturer intends to sell the device in a sterile condition
The words “for single use only” if the device is intended for that purpose
The expiry date of the device expressed in day, month, and year
The medical conditions, purposes and uses for which the device is manufactured, sold, or represented, including the performance specifications of the device if those specifications are necessary for proper use unless self-evident to the intended user the directions for use, unless directions are not required for the safe and effective Use of the device.
Warnings, precautions, and limitations of product
Any special storage conditions applicable to the device
The labelling design shall not bear close resemblance to other products already registered by the Authority.

Who should make this Communication?

Manufacturer
Authorized Representative

When to make this Communication?

Before placing a medical device into the market.

Challenges and Opportunities for U.S. Firms

Ghana has very limited local production of pharmaceuticals and even less manufacturing of medical equipment and devices. The country relies on imports for approximately 85% of its total healthcare consumption. Private health facilities complement the public sector. Ghana has sought to introduce more private-sector participation into the healthcare sector. The most dynamic growth and most exciting opportunities will be found in privately funded hospitals and clinics and in the non-state-controlled portion of the pharmaceutical sector. Clients value the quality and convenience of private facilities.

Ghana’s demographics remain reflective of its lower-middle income status: the average life expectancy is 60.9 years and infant mortality remains far above the world average (43 vs. 32 deaths per 1,000 live births in 2015). Ghana has a full range of diseases endemic to Sub-Sahara Africa: cholera, typhoid, pulmonary tuberculosis, chicken pox, yellow fever, measles, infectious hepatitis, malaria, and schistosomiasis are all endemic in Ghana.

Despite these challenges, the country does have a strong and growing middle class and a large number of expatriate Ghanaians are choosing to return to participate in one of Africa’s fastest growing economies.

Ghana’s colonial history still impacts the presence of competitors in the market-European, and particularly British, brands have a distinct advantage with Ghanaian consumers. Ghana’s Food and Drugs Authority (FDA) is closely modelled after the European Medicines Agency (EMA), providing an additional advantage to those companies. In the last 20 years there has been a growing presence in Ghana by Indian and Chinese companies selling into the health care sector. Chinese companies in particular are aggressively pursuing opportunities in West Africa and seeking partners to manufacture or assemble products in Ghana.

As both Indian and Chinese companies have become more active in Ghana’s market there has been a corresponding rise in the amount of counterfeit pharmaceutical products. The wide availability of counterfeit (and ineffective) malaria medications has caused particular concern. In response, the United States Pharmacopeia Commission (USP) established a presence in Ghana to provide assistance in the identification of counterfeit and substandard medicines. USP now has an active clinical lab in Accra working to build local capacity within Ghana’s healthcare industry.

Ghana’s appetite for medical services will continue to grow. As referenced earlier, Ghanaian consumers are extremely price sensitive, including their expenditures on health care products and services.

Strategies for Success

To succeed in Ghana's medical equipment market, companies should consider the following strategies:

Focus on Affordable and Reliable Equipment: Public and private hospitals in Ghana often struggle to find high-quality medical equipment that they can afford.
Explore Refurbished Equipment Options: Doctors and surgeons in Ghana are often delighted to find out that they can reduce device costs by up to 50% or more by purchasing reliable refurbished medical equipment from the USA.
Partner with Local Distributors: There are few medical device companies in Ghana and the majority of those companies are located in Accra. The short supply of medical equipment companies leaves many hospitals and doctors without a local source for medical devices.
Ensure FDA Compliance: Choosing a company that is registered with the USA FDA is always recommended to guarantee product quality.

The growth of Ghana’s medical market should create opportunities for U.S firms in the areas of hospital design and construction, consulting, and medical technologies ranging from cardiovascular and telemedicine to diagnostic equipment and more. medical companies are globally renowned for their innovation and commitment to quality, along with effective after-sales service, qualities that are highly attractive to probable foreign buyers.